Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

14.30
-0.1000-0.69%
Post-market: 14.400.1000+0.70%17:40 EDT
Volume:3.25M
Turnover:46.56M
Market Cap:1.41B
PE:-2.45
High:14.70
Open:14.43
Low:14.13
Close:14.40
52wk High:39.89
52wk Low:13.81
Shares:98.32M
Float Shares:80.72M
Volume Ratio:0.31
T/O Rate:4.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8279
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-24.22%
PB:-4.83
PE(LYR):-2.45

Loading ...

Ultragenyx price target lowered to $25 from $50 at H.C. Wainwright

TIPRANKS
·
Sep 03

Stocks to Watch: Snowflake, Broadcom, HPE, Ultragenyx

Dow Jones
·
Sep 03

Ultragenyx Pharma is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Sep 03

Ultragenyx Pharmaceutical Shares Crash 45% After Angelman Syndrome Drug Trial Disappoints

Trading Random
·
Sep 03

Ultragenyx Pharmaceutical Inc. : Baird Cuts to Neutral Rating; Cuts Target Price to $16 from $40

THOMSON REUTERS
·
Sep 03

Ultragenyx Pharmaceutical Inc. : TD Cowen Cuts Target Price to $18 from $49

THOMSON REUTERS
·
Sep 03

Ultragenyx Pharmaceutical Inc. : Canaccord Genuity Cuts Target Price to $37 from $83

THOMSON REUTERS
·
Sep 03

Ultragenyx downgraded to In Line from Outperform at Evercore ISI

TIPRANKS
·
Sep 03

Evercore ISI downgrades Ultragenyx Pharmaceutical (RARE) to a Hold

TIPRANKS
·
Sep 03

Ultragenyx downgraded to Market Perform from Outperform at William Blair

TIPRANKS
·
Sep 03

William Blair downgrades Ultragenyx Pharmaceutical (RARE) to a Hold

TIPRANKS
·
Sep 03

Ultragenyx Says Phase 3 Study on Rare Neurogenetic Disorder Missed Primary, Secondary Endpoints; Shares Fall After-Hours

MT Newswires Live
·
Sep 03

Ultragenyx Pharmaceutical to Cut Costs After Drug Trial Misses Endpoints

Dow Jones
·
Sep 03

Ultragenyx's Rare Disease Drug Fails in Late-Stage Trial

Reuters
·
Sep 03

Ultragenyx Announces Phase 3 Aspire Results in Angelman Syndrome

THOMSON REUTERS
·
Sep 03

Ultragenyx Pharmaceutical - Safety Profile in Aspire Study Consistent with Phase 1/2

THOMSON REUTERS
·
Sep 03

Ultragenyx Pharmaceutical - to Evaluate Apazunersen Program and Implement Significant Expense Reductions

THOMSON REUTERS
·
Sep 03

Ultragenyx Pharmaceutical - Expects to Continue Toward Profitability in 2027

THOMSON REUTERS
·
Sep 03

Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome

GlobeNewswire
·
Sep 03

Ultragenyx Unit Amlogenyx Presents at Wells Fargo Healthcare Conference Sept. 8

Reuters
·
Sep 02